コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ties for heart repair, disease modeling, and drug development.
2 ditional structural dynamics data to support drug development.
3 and advances its validation as a target for drug development.
4 orders and, thus, is an important target for drug development.
5 active target for anti-human cytomegalovirus drug development.
6 GPCR function that offer new opportunity for drug development.
7 work that may serve as viable candidates for drug development.
8 loration of novel analogues in antimicrobial drug development.
9 different pull incentives for antibacterial drug development.
10 r people with HIV and the planning of future drug development.
11 ion) is a highly sought-after goal in cancer drug development.
12 olleagues discuss an open source approach to drug development.
13 cell membrane permeability to enter into CNS drug development.
14 ost LC3 represents a target for antimalarial drug development.
15 is a validated target for tuberculosis (TB) drug development.
16 f diverse biological events and important in drug development.
17 erism at D3R and provides leads toward novel drug development.
18 may be relevant to Biotechnology as well as Drug Development.
19 g the underlying mechanisms is important for drug development.
20 ore are proposed to be potential targets for drug development.
21 pularity as potential therapeutic targets in drug development.
22 ther their specificity can be sufficient for drug development.
23 is study may be important for novel anti-HIV drug development.
24 ve conformation may advance structure-guided drug development.
25 EGylated molecules is critical for PEGylated drug development.
26 tions in personalized medicine as well as in drug development.
27 pports its potential as a lead candidate for drug development.
28 esents a promising lead compound for further drug development.
29 us for economic incentives for antibacterial drug development.
30 el systems for mechanistic investigation and drug development.
31 racterization of those disorders and enhance drug development.
32 represent a potential target for future PAH drug development.
33 ated molecules can accelerate the process of drug development.
34 pidly becoming an attractive alternative for drug development.
35 educe the total time and cost of traditional drug development.
36 to explore LdTyrRS as a potential target for drug development.
37 us making this scaffold a good candidate for drug development.
38 tential for targeting the APP673 site for AD drug development.
39 most common cause of attrition in late-phase drug development.
40 ly, identifying lead compounds for anti-ZIKV drug development.
41 ament function in the context of anti-cancer drug development.
42 gene]) channel are a major safety concern in drug development.
43 ibilities and challenges of pathway-specific drug development.
44 protein expression might form the basis for drug development.
45 ase) that is an attractive target for cancer drug development.
46 s (NHPs) is a common animal model for ocular drug development.
47 g alternative to classical binding sites for drug development.
48 ight p110delta as a target for antipsychotic drug development.
49 proteasome as a viable target for anticancer drug development.
50 s is imperative for oncology diagnostics and drug development.
51 d compound discovery and optimization during drug development.
52 patient safety while advancing antibacterial drug development.
53 lock is assessed in the preclinical phase of drug development.
54 nsights for genotypic screening and to guide drug development.
55 ors that could serve as backbones for future drug development.
56 ns (ADRs) are a central consideration during drug development.
57 bility across lipid membranes is crucial for drug development.
58 erm use and highlights the need for rational drug development.
59 ep that can ultimately be targeted for novel drug development.
60 get at the right phase of illness for future drug development.
61 olecules, providing a new diagnostic tool in drug development.
62 evelopment, Global Alliance for Tuberculosis Drug Development.
63 esting in the context of further advances in drug development.
64 el for the next generation of cardiovascular drug development.
65 the biological actions of PPPs and to guide drug development.
66 nzymes makes them impractical candidates for drug development.
67 gy and identify lead compounds for anti-ZIKV drug development.
68 in AD brains and can be very instructive for drug development.
69 relevant genes for downstream biomarker and drug development.
70 ghts into disease pathogenesis and informing drug development.
71 e attention as a potential discovery tool in drug development.
72 its Web API to be used in various tools for drug development.
73 g channel function and as lead compounds for drug development.
74 almitoylation, may improve the prospects for drug development.
75 orms within the needs of different phases of drug development.
76 ding starting points for anti-onchocerciasis drug development.
77 determining this lag phase is important for drug development.
78 t is a prominent target for chemotherapeutic drug development.
79 umour growth are an important goal in cancer drug development.
80 tant tools in cancer research and anticancer drug development.
81 cell communication, biomarker discovery, and drug development.
82 ranslation of this research to many areas of drug development.
83 ents a target for anticancer or antidiabetic drug development.
84 y oxidases that can be exploited for anti-TB drug development.
85 al respiratory oxidases for antituberculosis drug development.
86 d spaces may reveal new opportunities for Pt drug development.
87 rmous impact on disease diagnosis and in the drug development.
88 ls and could represent new possibilities for drug development.
89 OT supplementation may be advantageous in OT drug development.
90 in the host are now frequently used to guide drug development.
91 ailability, which limits their potential for drug development.
92 that TCMPs possess interesting features for drug development.
93 ities, may be the basis for future liposomal drug development.
94 ades may be novel targets for antidepressant drug development.
95 AS crystal structures, which will facilitate drug development.
96 these chaperones are attractive targets for drug development.
97 nterface as a target site for antiretroviral drug development.
98 e translational studies and efforts in early drug development.
99 resents a potential target for antimicrobial drug development.
100 hysiologically relevant context has hampered drug development.
101 the frontiers of human disease modeling and drug development.
102 ith the aim to support clinical research and drug development.
103 e the potential to improve the efficiency of drug development.
104 lic profiling data with genetics can enhance drug development.
105 es a new and novel target for rational P2X7R drug development.
106 tractive but unexploited target for clinical drug development.
107 ents represent a challenge to adjuvant ccRCC drug development.
108 mendous opportunities for basic research and drug development.
109 clinical genetics and may offer insights for drug development.
110 thereby substantially expediting the pace of drug development.
111 s could improve the safety and efficiency of drug development.
112 efficiency of clinical trials and accelerate drug development.
113 human cancers and is a promising target for drug development.
114 ical factor guiding dosage form selection in drug development.
115 hat are potential candidates for anti-fungal drug development.
118 example of enthalpy-entropy compensation in drug development accompanied with a likely explanation o
119 he presence of heterocycles commonly used in drug development affects the efficiency of (18)F-fluorin
121 The essential enzyme CYP121 is a target for drug development against antibiotic resistant strains of
122 ts in living organisms and as candidates for drug development against several cancer variants and hum
123 o detect ion fluxes and thus be utilized for drug development aimed at ion channel opener- or inhibit
124 r diagnostics, extracorporeal therapies, and drug developments allow for precise individual decision
126 t this miRNA may serve as a novel target for drug development and a biomarker for MDD pathogenesis.
128 molecules has potential for applications in drug development and as tools for chromatin research.
129 and holds great potential in antithrombotic drug development and assessing platelet activity in heal
134 ese data render 15a a promising compound for drug development and confirms high receptor occupancy as
135 cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods t
137 sample analysis, separation, chemotaxis, and drug development and injection-require control and preci
139 ss, identify an innovative target for future drug development and may provide an effective treatment
140 or unforeseen adverse effects that challenge drug development and mitigate against the empiric combin
142 l research via clinical applications such as drug development and patient-specific approaches as well
143 ulation-guided approaches to anti-arrhythmic drug development and patient-specific therapeutic interv
144 s for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorder
145 PET is now seen as a promising tool for drug development and precision medicine-that is, a metho
146 el provide opportunities for future rational drug development and probes for exploring the role of th
149 This seems mandatory in order to optimize drug development and to facilitate the accessibility of
151 or a given protein is a crucial component of drug development and understanding their biological effe
154 ocess between basic science discovery, early drug development, and definitive clinical testing in piv
157 osis, molecular testing, disease monitoring, drug development, and personalized and precision medicin
158 of nonexudative AMD are needed to accelerate drug development, and the availability of optical cohere
159 by day, with novel target discoveries, novel drug development, and use of novel combination treatment
163 l-cycle arrest, as well as pediatric-focused drug development, are critical for the advancement of dr
164 is a key player in mitosis and a target for drug development as it is upregulated in multiple cancer
165 mation may provide a structural platform for drug development, as a small molecule that rescues Torsi
166 ity of health care systems and would improve drug development, as it would pressure pharmaceutical co
167 comprehensive suite of in vitro preclinical drug development assays that can be used as a tool-box t
169 n delivery is one of the major challenges in drug development because of the high number of patients
170 re essential for target characterization and drug development, but few assays employ techniques or re
171 iative (CTTI) seeks to advance antibacterial drug development by streamlining HABP/VABP clinical tria
172 ing plays a fundamental role in oncology and drug development, by providing a non-invasive method to
173 ted small molecules relevant to neuroscience drug development can be prepared in a stereochemically c
175 ance on inadequately validated biomarkers in drug development can lead to harm to trial subjects and
178 op conducted by the Jumpstarting Brain Tumor Drug Development Coalition and the US Food and Drug Admi
180 efficacy in randomised controlled trials for drug development could be enhanced by predictive biomark
184 is an attractive alternative to the de novo drug development due to the potential for significantly
186 etases have been the focus of anti-infective drug development efforts and two aaRS inhibitors have be
187 al sources, rendering analogue synthesis and drug development efforts extremely resource-intensive an
188 roliferation of leukemic cells, with current drug development efforts focusing on antagonists and blo
191 nd blood infection, emphasizing the value of drug development efforts targeted toward those virulence
192 osteric PTP inhibitors may help reinvigorate drug development efforts that focus on this important fa
193 eted therapies, and may help to direct novel drug development efforts to overcome acquired drug resis
196 erein, we develop novel models to facilitate drug development: EGS strain T. gondii forms cysts in vi
197 types, and biology, together with a changing drug development environment, have created the need to r
198 es that have suggested molecular targets for drug development for ASD and the state-of-the-art of med
203 sses progress toward and challenges impeding drug development for inhibiting or evading P-gp in the c
205 ors can be applied in the first stage of the drug development for testing the interactions of new dru
207 iscuss the latest advances on anti-integrase drug development for the treatment of AIDS and the utili
209 s as peptide therapeutics for pharmaceutical drug development for treatment of T-cell-mediated disord
211 ene regulatory mechanisms have had impact on drug development, fueling excitement in the lay public a
212 rarely modeled accurately during preclinical drug development, hampering predictions of clinical drug
216 rontal cortex and hippocampus, some focus in drug development has shifted to early prevention of cell
220 nd VP24, represents an attractive target for drug development; however, the molecular determinants th
221 abolism and should be useful for preclinical drug development.Human liver chimeric mice are increasin
222 h efforts will not only help to generate new drug development ideas and strategies, but also will ref
224 ovel anti-human immunodeficiency virus (HIV) drug development.IMPORTANCE The Vpr and its paralog Vpx
231 is promising approach opens new horizons for drug development in obstetrics that could greatly impact
234 y, we consider the implications for rational drug development, in particular regionally selective dop
235 e being made to increase the productivity of drug development, including a refocusing on the study of
238 ion medicine-guided approach to novel cancer drug development is challenged by high intratumor hetero
242 ly required, however a major challenge to TB drug development is the lack of predictive pre-clinical
246 siology of AS and thus potential targets for drug development may be different according to sex.
248 ture, we argue that investment in ophthalmic drug development must continue to cover the whole transl
249 he implications for biology and antimalarial drug development of companion studies that establish the
250 nus of FGF14 are well positioned targets for drug development of PPI-based allosteric modulators of N
251 ursued, such as the modification of existing drugs, development of new drugs, or combination of novel
252 fection that may help define new targets for drug development or new prognostic tests, to improve pat
253 of human NRs, validating them as targets for drug development or providing new insights into structur
254 tive metabolism by 3A4 is often a concern in drug development owing to potential drug-drug interactio
255 immune functional studies in the preclinical drug development paradigm for cancer nanomedicines, and
256 Here, we discuss the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and
257 e on recent developments in the tuberculosis drug-development pipeline (including new and repurposed
258 romising anti-obesity medications are in the drug-development pipeline, the most promising drugs are
259 f LSCs are now being made in an era in which drug development pipelines offer the potential to specif
260 ntial to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS
269 y data sets to accelerate public and private drug development programs for rare disease is demonstrat
270 able exceptions, the frequency of successful drug development programs has fallen as most novel thera
272 elow the threshold of interest for dedicated drug development programs, and this disease is so rare t
275 tential for targeting the APP673 site for AD drug development.SIGNIFICANCE STATEMENT beta-site APP cl
276 r types, may be a viable strategy for future drug development.SIGNIFICANCE STATEMENT Memantine and ke
277 ) complexes is of fundamental importance for drug development since NRs regulate the transcription of
278 ss the array of challenges facing current HF drug development, so that future efforts may have a bett
282 ased lead discovery has emerged as a leading drug development strategy for novel therapeutic targets.
284 To explore PauA2 as a potential target of drug development, suppressors of the pauA2 mutant, which
286 with the same tumor type, this is an area of drug development that, rather than simply benefiting fro
287 sed in terms of the 3 pillars of survival in drug development, the first of which is characterization
288 ices are often justified by the high cost of drug development, there is no evidence of an association
289 ved pharmacodynamic biomarkers on subsequent drug development through a comprehensive analysis of pha
291 in small quantities has an essential role in drug development to eliminate their unwanted side effect
293 an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the
295 clusion, Nos2 (-/-) mice are a predictive TB drug development tool owing to their consistent developm
297 on the process and ethics of biomarker-based drug development, we conducted a systematic portfolio an
298 inical environment of pediatric oncology and drug development; we provide specific recommendations fo
299 and a mechanism of action-based approach to drug development will accelerate the delivery of new the
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。